neurologix inc (NRGXQ) Details

Neurologix, Inc., a development stage company, engages in the research and development of proprietary treatments for disorders of the brain and central nervous system primarily using gene therapies. Its treatments are designed as alternatives to conventional surgical and pharmacological treatments. The company primarily focuses on the development of a therapeutic product to meet the needs of patients suffering from Parkinson’s disease. Its core technology, NLX-P101, completed Phase II clinical trial of gene transfer for the treatment of advanced Parkinson’s disease. Neurologix also focuses on developing therapies to treat other neurodegenerative and metabolic disorders, including therapies relating to epilepsy, Huntington’s disease, and depression, as well as metabolic disorders, including genetically-based obesity. The company was founded in 1999 and is headquartered in Fort Lee, New Jersey. On March 16, 2012, Neurologix, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

neurologix inc (NRGXQ) Top Compensated Officers